Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn’s Disease.

Related Articles Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn’s Disease. Inflamm Bowel Dis. 2019 Nov 15;: Authors: Bashir NS, Walters TD, Griffiths AM, Ito S, Ungar WJ Abstract BACKGROUND: Anti-tumor necrosis factor-α (anti-TNF-α) treatments are increasingly used to treat pediatric Crohn’s disease, even without a prior trial of immunomodulators, but the cost-effectiveness of such treatment algorithms has not been formally examined. Drug plan decision-makers require evidence of cost-effectiveness to inform funding decisions. The objective was to assess the incremental cost-effectiveness of early intervention with…

Read More

The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease.

Related Articles The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Nov 15;: Authors: Thakur ER, Sansgiry S, Kramer JR, Waljee AK, Gaidos JK, Feagins LA, Govani SM, Dindo L, El-Serag HB, Hou JK Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) are more susceptible to mental health problems than the general population; however, temporal trends in psychiatric diagnoses’ incidence or prevalence in the United States are lacking. We sought to identify these…

Read More

Reply – Associations between drug exposure and outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Reply – Associations between drug exposure and outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019 Nov 12;: Authors: Bergquist A, Stokkeland K, Bottai M, Söderberg-Löfdal K PMID: 31730911 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31730911?dopt=Abstract

Read More

Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse.

Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse. Inflamm Bowel Dis. 2019 Nov 14;: Authors: Hansen TM, Sabourin BC, Oketola B, Bernstein CN, Singh H, Targownik LE Abstract BACKGROUND: It is unknown whether cannabis users self-medicating their inflammatory bowel disease (IBD) symptoms are more likely to have comorbid mental health or personality risk factors associated with an increased potential for substance misuse compared with recreational cannabis users. METHODS: We surveyed individuals with IBD about their cannabis use, their mental health symptoms, and personality risk factors…

Read More

Clostridium Difficile and Increased Risk of Surgery in Crohn’s Disease. Can Early Microbial Signatures Forecast Risk of Disease Progression?

Clostridium Difficile and Increased Risk of Surgery in Crohn’s Disease. Can Early Microbial Signatures Forecast Risk of Disease Progression? Inflamm Bowel Dis. 2019 Nov 14;: Authors: Goyal A PMID: 31725870 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31725870?dopt=Abstract

Read More

Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn’s Disease.

Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn’s Disease. Inflamm Bowel Dis. 2019 Nov 14;: Authors: Hellmann J, Andersen H, Fei L, Linn A, Bezold R, Lake K, Jackson K, Meyer D, Dirksing K, Bonkowski E, Ollberding NJ, Haslam DB, Denson L Abstract BACKGROUND: Clostridioides difficile infection and colonization are common in pediatric Crohn’s disease (CD). Our aims were to test the relationship between C. difficile positivity and bowel resection surgery and to characterize microbial shifts associated with C. difficile carriage and…

Read More

Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis.

Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci. 2019 Nov 13;: Authors: Bossa F, Biscaglia G, Valvano MR, Costantino G, Lauria A, Clemente R, Ferracane C, Shahini E, Mendolaro M, Grossi L, Mazzuoli S, Rispo A, Pranzo G, Sebkova L, Tursi A, Miranda A, Patturelli M, Spagnuolo R, Ricciardelli C, Sgarro C, Paese P, Inserra G, Azzarone A, Nardone O, Fries W, Buccianti N, Privitera AC, Principi MB, Cappello M, Guglielmi FW, Romano M, Riegler G, Fanigliulo L, Melina…

Read More

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis.

Related Articles Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. Gastroenterology. 2019 Nov 08;: Authors: Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J Abstract BACKGROUND AND AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis (UC). METHODS: In a phase 2,…

Read More

DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN’S DISEASE BASED ON SERUM LEVELS OF PROTEINS.

Related Articles DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN’S DISEASE BASED ON SERUM LEVELS OF PROTEINS. Gastroenterology. 2019 Nov 08;: Authors: D’Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS Abstract BACKGROUND & AIMS: Non-invasive tests…

Read More
<< Go Back